Trump Signs Psychedelic Research Order

The order instructs health authorities to expedite the review of clinical trials, following advocacy from veteran groups and high-profile figures like podcaster Joe Rogan.

Trump signed the order in the Oval Office, emphasizing the need for innovative treatments for depression and addiction.

While some medical experts have welcomed the push for more data, others have warned about the potential heart risks and psychological dangers associated with unregulated use.

The decision marks a significant shift in federal drug policy, potentially opening the door for the medicalization of previously banned substances.